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Honokiol (HK), a biphenolic neolignan isolated from Magnolia ofﬁcinalis, has been reported to possess
anti-inﬂammatory and anti-angiogenic activaties. In this study, our aim was to investigate anti-psoriatic
activities of HK and the involved mechanisms. In vitro, the effects of HK on the regulation of Th1/Th2 and
TNF-a-induced NF-kB (p65) activation were analyzed by respective FCS and immunoﬂuorescence.
Additionally, the K14-VEGF transgenic model was used for the in vivo study. ELISA and Q-PCR were
performed to evaluate serum levels of Th1/Th2 cytokines and their corresponding mRNA expressions.
Effects on VEGFR-2 and p65 activation, as well as other angiogenic and inﬂammatory parameters were
studied by immunostainings. Importantly, we found that HK signiﬁcantly decreased the ratio of Th1/Th2-
expression CD4þ T cells and inhibited TNF-a-induced activation of NF-kB. The morphology and histo-
logical features of psoriasis were effectively improved by HK treatment. The expression of TNF-a and IFN-
g, and their corresponding mRNA levels were down-regulated and the expression of nuclear p65, VEGFR-
2, as well as related phosphorylated proteins (p-VEGFR-2, p-ERK1/2, p-AKT and p-p38) were also sup-
pressed. Overall, these results in our study suggested that HK exhibits anti-psoriatic effects through the
inhibition of NF-kB and VEGFR-2.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Psoriasis is a chronic inﬂammatory skin disorder characterized
by aberrant differentiation and proliferation of keratinocytes, T
lymphocytes inﬁltration and dilation of dermal blood vessels (1, 2).
It developed through the interactions between the skin and im-
mune system (3), which was considered to contain the response of
dominant Th1 cell, and dysfunction of Th2 cell (4, 5). Recently,
research has focused on Th17/Th22 cells and IL-23, which induced
the production of IL-17 and IL-22 by T cells (6). Plasmacytoid den-
dritic cells (pDCs), inﬁltrating in psoriatic lesions, also exacerbated
the Th17-mediated pathogenesis of psoriasis (7, 8). Furthermore,ax: þ86 028 85164060.
.
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).NF-kB has been proved to be a crucial factor in the initiation of the
inﬂammatory response of psoriasis (9). The classic form of NF-kB is
the heterodimer of the p50 and p65 (RelA) subunits, which contains
the transcriptional activation domain and sequestered in the
cytoplasm as an inactive complex by the inhibitory proteins IkBs.
Stimulation of cells led to phosphorylation and degradation of IkBs
and allows translocation of Rel/NF-kB to the nucleus, resulting in
expression of target genes (10).
Despite the prominent inﬂammatory process involved, angio-
genesis also participated in the pathogenesis of psoriasis (11).
Vascular endothelial growth factor (VEGF) has been demonstrated
to be important in the angiogenic progress observed in psoriasis
(12). Among the receptors of VEGF, VEGFR-2 is the primary trans-
ducer of VEGF signaling in physiological angiogenesis, and is
increasingly observed in the papillary dermal micro-vessels of
psoriatic patients (13, 14). Previous studies revealed that K14-VEGF
transgenic mouse model exhibited profound inﬂammatory condi-
tion mimicking psoriasis both by its phenotype and thenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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increased inﬁltration of leukocytes on endothelial cells are
observed, leading to persistent inﬂammation within the skin.
Vascular inﬂammatory markers including intercellular cell adhe-
sion molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1), and E-selectin in inﬂammatory blood vessels were
overexpressed. Other previous reports also proved that K14-VEGF
transgenic mouse model is a convenient and valuable tool for
anti-psoriatic studies (16, 17).
Honokiol (HK) is a small-molecule natural product isolated from
Magnolia species that possessed extensive anti-inﬂammatory ef-
fects in arthritis and allergic asthma (18, 19). HK also exerted
excellent inhibition efﬁcacy on angiogenesis by interfering with
phosphorylation of VEGFR-2 in vitro and in vivo (20). Thus, on the
basis of those anti-inﬂammatory and anti-angiogenic properties,
we want to verify whether HK can possess anti-psoriatic effect and
the potential mechanism in this study.2. Materials and methods
2.1. Animals
K14-VEGF transgenic mice were purchased from Jackson Labo-
ratories (Bar Harbor, ME, USA). Animal experiments were approved
by our Institutional Animal Care and Use Committee of the Sichuan
University in China (IACUC number: 20100318).2.2. In vitro permeation study
Honokiol (98%)was initially isolated from the Magnolia ofﬁci-
nalis Rehd. Et Wils in our laboratory (21). In vitro permeation study
of HK cream (0.5%) was performed through skin using ﬂat ﬂange
Franz diffusion cells.2.3. In vitro ﬂow cytometry analysis
Splenocytes of BALB/c mice were harvested by dissociation
through a wire mesh. Spleen lymphocytes of 2  106/ml were
placed in 24-well plates, and incubated with ConA (5 mg/ml) for
72 h. Then PMA (25 ng/ml) and monensin (BioLegend, USA) (3 mM)
were added in and incubated for 4 h at 4 C. Different concentra-
tions of HK (5, 10 and 20 mg/ml) were added. Cultures without
exogenous stimuli were included as normal controls. Then samples
were stained with CD3-APC-Cy7, CD4-PE, CD8-FITC, IFN-g-PECY7
and IL-4-APC (BioLegend, USA) according to methods described
before (22). All analysis was conducted using a FACS Calibur ﬂow
cytometer. The ratio of IFN-g- and IL-4 e positive in CD4þ cells was
calculated.2.4. In vitro immunoﬂuorescence analysis
HUVEC cells were treatedwith HK (2.6 mg/mL) for 24 h, and then
with TNF-a (20 ng/ml, Prepro Tech, USA) for 1 h. Cells without any
treatment were as negative control. The cells were ﬁxed, washed
and treated with PBS containing 0.05% of Triton X-100 for 2 h. P65
antibody (Santa Cruz Biotechnology, USA) was incubated with the
cells overnight at 4 C. The cells were incubated with FITC antibody
(Invitrogen, China) for 2 h at 4 C. For nuclear staining, the cells
were incubated with DAPI (Beyotime, China) for 10 min. The pic-
tures were taken by ﬂuorescence microscopy (Olympus, Tokyo,
Japan).2.5. Treatment of K14-VEGF transgenic model with HK cream
The K14-VEGF transgenic mice (3 months old) with moderate
psoriatic phenotype were divided into nine groups randomly (four
mice of per group): Five groups were topically treated with cream
base, HK cream (0.1%, 0.5% and 1.0%) and Tretinoin ointment
(0.025%, Huabang pharmaceutical, China) at 4 weeks. Other four
groups received treatment with cream base and HK cream (0.5%) at
2 and 6 weeks, respectively. The mice were treated by cream with
the weight of 0.3 g/cm2 on the back ears on both sides once daily.
The cream base contained stearic acid, glycerin monostearate,
white Vaseline, liquid parafﬁn, glycerin, distilled water, water-
soluble azone, SDS, propylparaben and DMSO (<0.1%). After treat-
ment, the photos of ear were obtained, and the ear tissue was
harvested for subsequent histologic and immunohistochemical
analyses. The FVB/n wild type mice without treatment were for
normal control.
2.6. ELISA and quantitative PCR
The serum levels (IFN-g, TNF-a, IL-2, IL-4 and IL-10) of mice
treated for 4 weeks were measured by using ELISA kits (R&D Sys-
tems, Minneapolis, MN) according to the manufacturer's
instructions.
The expression of IFN-g and TNF-a mRNA in ear tissue of mice
treated for 4 weeks was measured by Q-PCR as previously
described (23, 24). Total content of RNA was isolated from ear by
using Trizol reagent (Invitrogen, USA). RNA (2 mg/each) was
reverse-transcribed to obtain cDNA by using the PTC-200 DNA
Engine (MJ Research, USA).
2.7. Western blot analysis
Ear tissue of mice treated for 4 weeks were lysed, incubated on
ice with frequent vortexing and centrifuged (18,000 g, 20 min).
Supernatant was removed and protein content was quantiﬁed.
Proteins were mixed with 5  loading buffer, heated at 95 C for
5 min, separated on polyacrylamide gels, and then transferred. The
membranewas incubatedwith antibodies overnight at 4 C, and 1 h
at room temperature with second antibodies of VEGFR-2 and
p-VEGFR-2.
2.8. H&E and immunohistochemistry
Ear samples of animalmodels were ﬁxed in 10% neutral formalin
and embedded in parafﬁn for histological analysis. Sections (3~5 mm
thick) were subjected to staining with H&E to evaluate the histo-
logical changes. Fixed sections of K14-VEGF transgenic mice treated
for 4 weeks were used for immunostaining. Staining for RelA (p65)
was performedwith anti-mouse p65 and (diluted 1:400, Santa Cruz
Biotechnology, USA). Stainings for vascularization and adhesion
molecules were performed with mouse monoclonal antibodies
anti-mouse platelet-endothelial cell adhesion molecule-1(PECAM-
1) (CD31, diluted 1:400, Santa Cruz Biotechnology, USA), anti-
mouse intracellular adhesion molecule ¼ 1 (ICAM-1) (CD54,
diluted 1:50, Boster, China), anti-mouse E-Selectin (CD62E, diluted
1:50, Boster, China) and VCAM-1(CD106, diluted 1:100, Santa Cruz
Biotechnology, USA) as themanufacturer's instructions. Staining for
cell nuclear antigen proliferating was performed with anti-mouse
PCNA (diluted 1:500, Abcam, Cambridge, MA, USA). Stainings for
VEGFR were performed with anti-mouse VEGFR-2 (Flk-1, diluted
1:600, Cell Signaling Technology), p-VEGFR-2 (p-Flk-1, diluted
1:200), Akt (diluted 1:100), p-Akt (diluted 1:400), ERK1/2 (diluted
1:600), p-ERK1/2 (diluted 1:400), p38 (diluted 1:100) and p-p38
(diluted 1:100) following the manufacturer's instructions. The
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Images were acquired using Olympus CKX41 and DP75 and
processed with Image-Pro Plus 5.0 (Media Cybernetics, Silver
Spring, MD).Fig. 1. Flow cytometry and immunoﬂuorescence analysis. Effects of HK on the expression
respectively analyzed using ﬂow cytometry. (D) HK markedly inhibited TNF-a-induced activ2.9. Statistics
The data of statistical analysis are presented as mean ± SD.
Differences between the groups were tested by Student's t-test.of CD3 (A), CD4 and CD8 (B) in T lymphocytes and the level of IFN-g and IL-4 (C) were
ation of NF-kB in HUVEC cells by immunoﬂuorescence (original magniﬁcation,  200).
Table 1
The percentage of CD3, CD4, CD8, IFN-g and IL-4 expression in spleen lymphocytes of mice (x ± SD, %).
CD3 CD4 CD8 IFN-g (Th1) IL-4 (Th2) Th1/Th2
Untreated 87.6 ± 2.0 37.4 ± 3.3 3.7 ± 0.9 1.2 ± 0.2 1.1 ± 0.5 e
Control 88.3 ± 1.2 35.1 ± 3.0 2.5 ± 0.4 22.4 ± 4.5# 10.2 ± 2.2# 2.32 ± 0.86
HK (5 mg/ml) 81.7 ± 1.7** 26.6 ± 2.8* 2.6 ± 0.6 8.5 ± 1.2** 10.1 ± 1.7 0.85 ± 0.16*
HK (10 mg/ml) 80.1 ± 0.8** 20.8 ± 2.7** 2.9 ± 0.6 2.1 ± 0.5* 11.3 ± 1.1 0.21 ± 0.05*
HK (20 mg/ml) 76.2 ± 2.5** 19.0 ± 1.0** 2.8 ± 0.9 1.7 ± 0.4* 12.3 ± 2.2 0.14 ± 0.02*
Data are presented as mean ± SD and were analyzed using Student's t test. (n ¼ 3, *P < 0.05, **P < 0.01 compared with Control, #P < 0.05 compared with untreated).
Fig. 2. HK normalizes the psoriatic phenotype in K14-VEGF transgenic mice (A) Ear gross of mice treated for 4 weeks (B) H&E staining of ear tissue treated with Tretinoin or
different doses of HK for 4 weeks (original magniﬁcation,  200). (C) H&E staining of ear tissue treated with HK (0.5%) for 2, 4 and 6 weeks (original magniﬁcation,  200). (D)
Pathological score showed that HK exhibits good therapeutic efﬁcacy dose-dependently. (E) Pathological score showed treatment of HK (0.5%) for 4 weeks exhibits the best efﬁcacy.
Data are presented as mean ± SD. (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
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USA), with a P value < 0.05 considered to be statistically signiﬁcant.Table 2
Baker score of K14-VEGF transgenic mice.
Groups 2weeks 4weeks 6weeks
FVB/n e 0.7 ± 0.27 e3. Results
3.1. In vitro permeation of HK through mouse skin
It was found that only 20% of HK was released in the receptor
chamber in the ﬁrst 6 h, and less than 40% of HK was released even
after 24 h (Supplementary Fig. S1).Control 3.5 ± 0.35 4.5 ± 0.71 5.3 ± 0.67
Tretinoin e 1.8 ± 0.45*** e
HK(0.1%) e 1.4 ± 0.22*** e
HK(0.5%) 1.7 ± 0.57### 1.1 ± 0.42*** 1.5 ± 0.61^^ ^
HK(1.0%) e 0.8 ± 0.27*** e
Data are presented as mean ± SD and were analyzed using Student's t test. (n ¼ 4,
***P < 0.001 compared with Control treated for 4weeks, ###P < 0.001 compared with
Control treated for 2weeks, ^^ ^P < 0.001 compared with Control treated for 6weeks).3.2. HK decreased the ratio of Th1/Th2- expression CD4þ T cells
As shown in Fig.1 and Table 1, the percentage of CD3þ, CD4þ and
CD8þ T cells showed no signiﬁcant difference after stimulation
compared with untreated group (P > 0.05). However, the percent-
age of IFN-g- and IL-4 -expressing CD4þ T cells increasedsigniﬁcantly after stimulation (P < 0.05). Interestingly, HK treat-
ment notably decreased both the percentage of CD3þ and CD4þ T
cells, but not CD8þ T cells (Fig. 1A, B).Furthermore, HK treatment
showed pronounced down-regulation on the percentage of IFN-g-
expressing cells, but no inﬂuence on IL-4-expressing cells (Fig. 1C).
Fig. 3. Effect on serum levels of Th1 and Th2 cytokines by ELISA and mRNA expression of IFN-g and TNF-a within ear tissue by Quantitative PCR. HK treatment decreased the
levels of TNF-a (A) and IFN-g (B), but not IL-4 (C) and IL-10 (D). Quantitative PCR data (E and F) showed a signiﬁcant down-regulation of mRNA levels of IFN-g and TNF-a by HK
treatment. Data are presented as mean ± SD. (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
Fig. 4. HK inhibited the nuclear expression of RelA (p65) and CD31 in a dose-dependent manner. (A) Representative pictures of immunostaining of RelA (p65) and CD31
(original magniﬁcation,  200). Quantitative of the mean nuclear p65 (B) and CD31 (C) positive area counted at  200. Data are presented as mean ± SD (*, p < 0.05; **, p < 0.01).
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Table 3
Effects of HK on p65, vascular markers and VEGFR2 signal.
Control Tretinoin HK (0.1%) HK (0.5%) HK (1.0%)
p65 571.6 ± 104.4 316.0 ± 94.7* 261.33 ± 92.6* 258.67 ± 66.5* 174.67**
CD31 948 ± 65.5 332 ± 44.3*** 631 ± 12.9** 428 ± 18.5* 329 ± 16.8***
ICAM-1 1320.3 ± 195.0 582.0 ± 203.7* 475.0 ± 182.6** 339.7 ± 174.8** 130.0 ± 27.5***
VCAM-1 497.3 ± 118.2 440.6 ± 61.0 368.0 ± 54.6 183.7 ± 30.6* 94.67 ± 16.6**
E-selectin 976.0 ± 146.0 708.3 ± 46.1* 754.3 ± 99.4 466.7 ± 91.4** 329.7 ± 91.3**
VEGFR2 561.0 ± 69.7 531.0 ± 65.0 e 184.0 ± 45.1** e
p-VEGFR2 303.7 ± 58.6 180.3 ± 55.6 e 77.7 ± 16.0** e
p-ERK1/2 600.7 ± 72.1 614.3 ± 33.3 e 324.0 ± 32.6** e
p-AKT 501.3 ± 25.6 137.7 ± 41.0*** e 138.3 ± 15.5*** e
p-p38 452.0 ± 60.1 408.3 ± 19.7 e 309.0 ± 50.9* e
Data are presented as mean ± SD and were analyzed using Student's t test. (n ¼ 4, *P < 0.05, **P < 0.01, ***P < 0.001 compared with Control).
Fig. 5. HK inhibited the expression of ICAM-1, VCAM-1 and E-selectin in a dose-dependent manner. (A) Representative pictures of immunostaining with antibodies to ICAM-1,
VCAM-1, and E-selectin (original magniﬁcation,  200). Quantitative of the mean ICAM-1(B), VCAM-1(C) and E-selectin (D)-positive area counted at  200. Bars, mean ± SD (n ¼ 4),
*p < 0.05, **p < 0.01, ***p < 0.001 vs. Control. (E) Western blotting of VEGFR-2 and p-VEGFR-2.
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J. Wen et al. / Journal of Pharmacological Sciences 128 (2015) 116e124122Consequently, Th1/Th2 balance analysis revealed that HK decreases
the ratio of Th1/Th2- expression CD4þ T cells dose-dependently
(Table 1).
3.3. HK inhibited TNF-a-induced activation of NF-kB in HUVEC cells
Nuclei were stained with DAPI (blue) and nuclear p65 was
analyzed by immunostaining (green). As shown in Fig. 1D, marked
localization of green ﬂuorescence in the nuclei was observed with
TNF-a treatment for 1 h, but cells pretreated with HK showedmuch
less localization in nuclei. The results indicated that HK inhibits
TNF-a-induced activation of NF-kB.
3.4. HK normalized psoriatic phenotype in K14-VEGF transgenic
mice
The ears of control group showed prominently enlarged, hy-
perplastic blood vessels on erythematous and scaly ear skin upon
gross inspection (Fig. 2A). But pronounced improvements were
observed in lesions of HK-treated groups. Compared with control
mice, which showed psoriasis-like histological changes such asFig. 6. HK decreased the expression of VEGFR-2 and p-VEGFR-2 signiﬁcantly. (A) Represe
mean VEGFR-2 (B) and p-VEGFR-2 (C)-positive area counted at  200. Bars, mean ± SD (n
p-VEGFR-2.acanthosis, formation of rete pegs, parakeratosis, thickening of the
sub-epidermal layer and inﬂammatory inﬁltration, HK treatments
showed signiﬁcant improvements in these phenotypes. (Fig. 2B)
Pathological score of the Baker score system (12) showed that HK-
and Tretinoin-treated groups exhibited lower score compared to
control group (Fig. 2D, Table 2). The results indicated that HK cream
showed good therapeutic efﬁcacy in a dose-dependent manner. In
addition, HK treatment at low dose (0.1%) showed no signiﬁcant
difference with Tretinoin (P > 0.05), but at middle (0.5%) and high
(1.0%) dose showed better efﬁcacy than Tretinoin (P < 0.05,
P < 0.01). Furthermore, in the time course study, both H&E (Fig. 2C)
and pathological score (Fig. 2E, Table 2) revealed that 4-week-HK
treatment showed the best efﬁciency.3.5. Effect of HK on serum levels of Th1 and Th2 cytokines
As shown in Fig. 3A and B, HK dose-dependently decreased TNF-
a and IFN-g levels, but had no effect on IL-4 and IL-10 production
(Fig. 3: CeD). The inhibition effect of HK (0.5% and 1.0%) is better
than positive control (P < 0.05, P < 0.05).ntative pictures of immunostaining (original magniﬁcation,  200). Quantitative of the
¼ 4). **p < 0.01 vs. Control. The arrowhead indicates the positive area of VEGFR-2 and
J. Wen et al. / Journal of Pharmacological Sciences 128 (2015) 116e124 1233.6. HK suppressed mRNA expression of IFN-g and TNF-a in ear skin
of K14-VEGF mice
To further conﬁrm the inhibition effect of HK on IFN-g and TNF-
a production, the mRNA expression of them was evaluated by
quantitative RT-PCR. The IFN-g and TNF-a mRNA expression in
control was higher than that in FVB/n mice. HK (0.5%) treatment
remarkably down-regulated the IFN-g and TNF-a mRNA levels
(Fig. 3: EeF), which indicated that HK suppressed the transcription
of IFN-g and TNF-a in gene levels.
3.7. HK inhibited nuclear expression of RelA (p65) and expression of
inﬂamed vascular markers
Immunostaining of RelA (p65) revealed that HK and Tretinoin
signiﬁcantly reduced the numbers of nuclear p65 positive cells
compared with control group (Fig. 4: A and B, Table 3). In addition,
HK suppressed the expression of CD31 (Fig. 4: A and C, Table 3) and
inﬂamed-vascular markers (Fig. 5: AeD, Table 3) in a dose-
dependent manner. Immunostaining of PCNA also revealed that
HK inhibited cell proliferation in a dose-dependent manner
(Supplementary Fig. S2).
3.8. HK inhibited the expression and phosphorylation of VEGFR-2,
Akt, ERK and p38
Western blot analysis of VEGFR-2 and p-VEGFR-2 showed a
down-regulation by HK (0.5%) treatment (Fig. 5E). Immunostaining
of VEGFR-2 and p-VEGFR-2 (Fig. 6) revealed that HK (0.5%) prom-
inently inhibited the expression of VEGFR-2 and phosphorylation of
VEGFR-2 (Table 3).Fig. 7. HK decreased the expression of p-ERK1/2, p-AKT and p-p38. (A) Representative p
p-ERK1/2 (B), p-AKT (C), p-p38 (D)-positive area counted at  200. The numbers of p-ERK1
represent mean ± SD (n ¼ 4), *p < 0.05, ***p < 0.001 as compared with Control.Since ERK1/2, AKT and p38 can also be regulated by VEGF signal
through VEGFR-2 (23), immunohistochemical studies with anti-
bodies to Akt, ERK1/2 and p38 and their phosphorylation proteins
were processed. The results demonstrated that HK signiﬁcantly
suppressed the phosphorylation of ERK1/2, AKT and p38 (Fig. 7,
Table 3). However, no inﬂuence on the expression of ERK1/2, AKT
and p38 was observed (Supplementary Fig. S3).
4. Discussion
Previous studies have revealed that IFN-g and TNF-a contrib-
uted to an initial anti-inﬂammatory efﬁcacy, which were related
with the activation of NF-kB (25, 26). HK has been reported to show
anti-inﬂammatory effects in TNF-a-stimulated rheumatoid arthritis
synovial ﬁbroblasts (27). In the study, HK signiﬁcantly decreased
the percentage of Th1-expression CD4þ T cells. However, no inﬂu-
ence on the Th2- expression CD4þ T cells was observed. Our results
also suggested that HK exerted anti-inﬂammatory effect by inhi-
bition of TNF-a-induced NF-kB activation in HUVECs.
Furthermore, we found that HK (0.1%) exhibited comparable
therapeutic efﬁcacy to Tretinoin and HK could improve the pheno-
type of psoriasis in a dose-dependent manner. In accordance with
previous study (28), Tretinoin showed more inﬂuence on Th1 cy-
tokines (IFN-g and TNF-a) than Th2 cytokines (IL-4 and IL-10).
Studies have also revealed that HK reduced the levels of TNF-a, IL-
1b and IL-17 in CIA mice (29). In our study, HK dose-dependently
reduced the expression and gene transcription of IFN-g and TNF-a,
but there was no signiﬁcant effect on IL-4 and IL-10. In addition,
down-regulation of nuclear p65 indicated that HK could suppress
the activation of NF-kB. As mentioned above, the action of TNF-
targeted agents was linked with down-regulation of NF-kBictures of immunostaining (original magniﬁcation,  200). Quantitative of the mean
/2, p-AKT and p-p38 positive cells in HK-treated mice ears decreased remarkably. Data
J. Wen et al. / Journal of Pharmacological Sciences 128 (2015) 116e124124transcriptional activity (30). Our results demonstrated thatHKcould
exhibit anti-TNF-a efﬁcacy through inhibition of NF-kB activity.
HK has been reported to inhibit the phosphorylation of AKT and
MAPK, and down-regulate the expression of VEGFR-2 in HUVECs
(20). In this study, both HK and Tretinoin showed pronounced in-
hibition effect on hyperplastic and inﬂamed cutaneous blood ves-
sels. HK could down-regulate the expression of VEGFR-2 and p-
VEGFR-2 in ear tissue while Tretinoin slightly reduced the expres-
sion of VEGFR-2. However, the phosphorylation of VEGFR-2 was
inhibited by Tretinoin. In addition, soluble VEGFR-2 was also down-
regulated by HK treatment (Supplementary Fig. S4). Previous
studies have demonstrated that the activity of p38, ERK1/2 and
PI3K/Akt were increased in lesional psoriatic skin (31, 32). Our re-
sults showed that HK had excellent inhibition effect on phosphor-
ylated ERK1/2 and AKT. Tretinoin selectively suppressed the
phosphorylation of AKT, which is different from previous reports
(33).
This study would be helpful for better understanding the rela-
tionship between inﬂammation and angiogenesis in psoriasis.
VEGFR-2 could participate in the inﬂammatory process through
p38, ERK1/2 and AKT pathway, which were upstream of NF-kB
pathway. Besides, the activation of NF-kB could induce the pro-
duction of inﬂammatory vascular markers (9). The mechanism by
which HK exhibited anti-psoriatic effects maybe like this: HK
inhibited VEGFR-2 signal through inhibition of p38, ERK1/2 and
AKT, then inhibited the activation of NF-kB and inﬂammatory
vascular markers. However, more focuses are still needed to further
illustrate its anti-psoriatic mechanism.
These studies suggested that HK exhibited potent anti-psoriatic
effects through the inhibition of NF-kB and VEGFR-2. Therefore, HK
is promising to be a novel anti-inﬂammatory and anti-angiogenic
agent in topical anti-psoriatic therapy.
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